Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaukos' Micro-Bypass Stents Work As First-Line Glaucoma Therapy

Executive Summary

Results of a 101-patient randomized clinical trial show that implantation of two iStent Trabecular Micro-Bypass stents is a viable initial treatment option, comparable to topical ocular hypotensive medications, in patients with newly diagnosed primary open-angle glaucoma.

You may also be interested in...



Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma

Glaukos Corp. announced on Dec. 27 it has submitted a pre-market approval application to US FDA for its second-generation minimally invasive glaucoma surgery (MIGS) iStent device used for treating glaucoma, the second-leading cause of blindness.

Market Intel: Micro-Invasive Glaucoma Implants Mark Hottest Growth Spot In Eye Surgery Products Market

The rising aging population and ever-increasing incidences of glaucoma and cataract are clearing a bright path for the ophthalmic surgical products market, which is expected to reach $9.4bn by 2021, a CAGR of 4.6% from 2016. Meddevicetracker expects that continued innovation in minimally invasive technologies and next-generation surgical systems, developed by giants like Alcon and smaller rivals, will address the need of hundreds of millions of people suffering from cataract and glaucoma, the two leading causes of blindness globally. In this feature, we'll take a closer look at the overall market and the key players in the individual segments of surgical systems, surgical instruments and IOLs. We'll take a deep dive into the smallest, yet fastest-growing MIGS devices segment and talk to surgeons about how they're transforming glaucoma management for their patients.

Glaukos Holds Lead In Microinvasive Glaucoma Surgery

Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT103878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel